Patents Assigned to The Washington University
-
Patent number: 12152280Abstract: The present invention provides methods for testing surgical fluid for biomarkers of disease, including cancer.Type: GrantFiled: September 30, 2021Date of Patent: November 26, 2024Assignees: DROPLET BIOSCIENCES, INC., The Washington UniversityInventors: Jose P. Zevallos, Aadel Chaudhuri, Stanley N. Lapidus
-
Patent number: 11920139Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.Type: GrantFiled: October 14, 2021Date of Patent: March 5, 2024Assignees: The Washington University, The Arizona Board of Regents for and on Behalf of Arizona State UniversityInventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
-
Publication number: 20220001189Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to he positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of tire one or more singularities delivered via the near-field configuration of the electrodes.Type: ApplicationFiled: July 19, 2021Publication date: January 6, 2022Applicant: The Washington UniversityInventors: Igor R. EFIMOV, Wenwen LI, Ajit JANARDHAN
-
Patent number: 11180765Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.Type: GrantFiled: August 11, 2020Date of Patent: November 23, 2021Assignees: The Arizona Board of Regents for and on behalf of Arizona State University, The Washington UniversityInventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
-
Patent number: 11097120Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.Type: GrantFiled: August 6, 2019Date of Patent: August 24, 2021Assignee: The Washington UniversityInventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
-
Patent number: 11083905Abstract: Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.Type: GrantFiled: August 6, 2019Date of Patent: August 10, 2021Assignee: The Washington UniversityInventors: Igor R. Efimov, Wenwen Li, Ajit H. Janardhan
-
Patent number: 10774334Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.Type: GrantFiled: December 5, 2019Date of Patent: September 15, 2020Assignees: Arizona Broad of Regents on Behalf of Arizona State University, The Washington UniversityInventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
-
Patent number: 10549108Abstract: A method for extinguishing a cardiac arrhythmia utilizes destructive interference of the passing of the reentry wave tip of an anatomical reentry through a depolarized region created by a relatively low voltage electric field in such a way as to effectively unpin the anatomical reentry. Preferably, the relatively low voltage electric field is defined by at least one unpinning shock(s) that are lower than an expected lower limit of vulnerability as established, for example, by a defibrillation threshold test. By understanding the physics of the electric field distribution between cardiac cells, the method permits the delivery of an electric field sufficient to unpin the core of the anatomical reentry, whether the precise or estimated location of the reentry is known or unknown and without the risk of inducting ventricular fibrillation. A number of embodiments for performing the method are disclosed.Type: GrantFiled: August 27, 2018Date of Patent: February 4, 2020Assignee: The Washington UniversityInventors: Igor R. Efimov, Valentin Krinski, Vladmir P. Nikolski
-
Publication number: 20190366109Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.Type: ApplicationFiled: August 6, 2019Publication date: December 5, 2019Applicant: The Washington UniversityInventors: Igor R. EFIMOV, Wenwen LI, Ajit JANARDHAN
-
Publication number: 20190358463Abstract: Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.Type: ApplicationFiled: August 6, 2019Publication date: November 28, 2019Applicant: The Washington UniversityInventors: Igor R. Efimov, Wenwen Li, Ajit H. Janardhan
-
Patent number: 10441805Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.Type: GrantFiled: October 9, 2017Date of Patent: October 15, 2019Assignee: The Washington UniversityInventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
-
Patent number: 10413741Abstract: Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.Type: GrantFiled: September 19, 2018Date of Patent: September 17, 2019Assignee: The Washington UniversityInventors: Igor R. Efimov, Wenwen Li, Ajit H. Janardhan
-
Patent number: 9885051Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.Type: GrantFiled: February 10, 2016Date of Patent: February 6, 2018Assignees: The Arizona Board of Regents for and on Behalf of Arizona State University, The Washington UniversityInventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
-
Patent number: 9814895Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.Type: GrantFiled: February 26, 2016Date of Patent: November 14, 2017Assignee: The Washington UniversityInventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
-
Patent number: 9297015Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.Type: GrantFiled: March 7, 2013Date of Patent: March 29, 2016Assignees: Arizona Board of Regents for and on behalf of Arizona State University, The Washington UniversityInventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
-
Patent number: 9289620Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.Type: GrantFiled: April 21, 2014Date of Patent: March 22, 2016Assignee: The Washington UniversityInventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
-
Publication number: 20150045847Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.Type: ApplicationFiled: April 21, 2014Publication date: February 12, 2015Applicant: The Washington UniversityInventors: Igor R. EFIMOV, Wenwen LI, Ajit JANARDHAN
-
Patent number: 8874208Abstract: Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.Type: GrantFiled: January 12, 2012Date of Patent: October 28, 2014Assignee: The Washington UniversityInventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
-
Publication number: 20140234841Abstract: In one aspect, the disclosure provides isolated nucleic acids, polypeptides, primers, and probes for the detection of mutations in a nucleic acid sequence for a DICER1 polypeptide.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicants: Children's Hospital and Clinics of Minnesota, The Washington University in St. LouisInventors: Ashley D. Hill, Paul Goodfellow, John R. Priest, Yoav Messinger
-
Publication number: 20140221614Abstract: A mineralized collagen matrix with an intrafibrillar and/or extrafibrillar gradient of mineralization for insertion replacement is disclosed. The intrafibrillar mineralization of the collagen matrix is formed by the addition of fetuin to the simulated body fluid. The gradient of intrafibrillar mineralization may stiffen the collagen matrix and simulate a natural insertion for improved cell infiltration and regeneration.Type: ApplicationFiled: January 31, 2014Publication date: August 7, 2014Applicant: The Washington UniversityInventors: Lester Smith, Stavros Thomopoulos